As part of Goodwin's webinar series, What's Next: Life Sciences at a Crossroads, Matthew Wetzel and Elizabeth Mulkey will be diving into highlights from the Trump 47 Executive Orders on Lowering Drug Prices and Increasing Domestic Manufacturer and Regulatory Relief to Promote Domestic Production of Critical Medicines, and Washington's current view of the biotech industry's relationship with China. They'll cover topics including BIOSECURE, rare disease impact, most favored nation pricing, and government recommendations for the future of U.S. drug production.
Register today to join Matt and Elizabeth on Tuesday 20th from 12:00 pm EST to 1:00 pm EST: https://bit.ly/42Ys79y
Can't make this event? Click here to see more information on What's Next: Life Sciences at a Crossroads!